PeptiDream Inc. disclosed the achievement of a milestone and receipt of payment under its joint research with MSD on 7 October, and its share price reacted to the news on 8 October. The earnings release showed that revenue increased in the interim period, but losses continued, with attention focused on future clinical development trends and partnering revenue.
PeptiDream Inc.’s share price recovered from around ¥1,075 to ¥1,072.5 between 9 and 16 October, rising ¥41.5, or 4.03% from the previous day, on 16 October. Trading volume on 14 October reached 1,532,900 shares, up 159% from the previous day, indicating that individual company-specific factors were being intermittently reflected in the share price.
On 7 October, the company disclosed the achievement of a milestone and receipt of payment under its joint research and development with MSD. On 8 October, reports said the stock rose for a third consecutive day on the joint research news, suggesting that company-specific factors have been influencing recent price movements.
According to the summary of the earnings release, revenue for the interim period announced on 12 August 2026 was ¥9.2 billion, up 8.0% year on year, while losses continued, with an operating loss of ¥2.5 billion and an interim loss of ¥2.0 billion. Research and development expenses were ¥2.6 billion and have been increasing, but full-year revenue of ¥32.0 billion and operating profit of ¥4.6 billion are expected, marking a return to profitability.
Key factors to monitor for future earnings include growing demand for PET diagnostics, expansion of the amyloid PET market and progress in the clinical development of products such as PD-L1, all of which are growth drivers for the radiopharmaceutical business. The company’s proprietary CA9-targeting RI candidate has begun a Phase 1 trial in the United States, while the recognition of milestone revenue from the HER2-targeting program for Novartis has been disclosed.